BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced fourth-quarter and record full-year 2022 financial results.

GeneDx today announced that company management will participate at the Cowen 43rd Annual Healthcare Conference in Boston, MA.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on significant progress made in the field of cannabis research.

Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Select Market at market open today, March 1, 2023.

BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of Understanding (MoU).

Catalyst Pharmaceuticals, Inc. announced that it will release its fourth quarter and full-year 2022 financial results after the market close on Wednesday, March 15, 2023.

Pliant Therapeutics, Inc. today announced senior management’s participation at the following investor events in March.

Centessa Pharmaceuticals plc today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines.

Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35th Annual Roth Conference, being held March 12-14, 2023 in Laguna Niguel, CA.